Fischer Medical Ventures' JV Partner, Nanyang Biologics, Wins Top Global AI Innovation Award

Nanyang Biologics (NYB.AI), the joint venture partner of Fischer Medical Ventures Ltd, has won the first prize at the SuperAI Genesis Startup Competition. The competition, which had over 700 startups from more than 100 countries, recognized NYB.AI for its groundbreaking approach to AI-powered drug discovery, particularly its focus on nature-derived compounds and strong regional applicability. Fischer Medical Ventures supports the development of NYB.AI's transformative nutraceuticals derived from natural plants and herbs. NYB.AI's proprietary DTIGN platform (Drug-Target Interaction Graph Neural Network) has several advantages, including 25% higher accuracy, 10x faster model training, 8x faster molecular docking, 64x improvement in hit-rate efficiency, and a 44.8% increase in bioactivity prediction accuracy. These advantages translate into accelerated drug development timelines, significant cost savings, and greater success rates.